Published in Br J Pharmacol on January 01, 1976
Serotonin and blood pressure regulation. Pharmacol Rev (2012) 1.41
p-Chlorophenylalanine: a specific depletor of brain serotonin. J Pharmacol Exp Ther (1966) 5.52
EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. IV. DISTRIBUTION OF MONOAMINE NERVE TERMINALS IN THE CENTRAL NERVOUS SYSTEM. Acta Physiol Scand Suppl (1965) 4.95
Construction and implantation of a permanent cannula for making injections into the lateral ventricle of the rat brain. Life Sci (1966) 3.54
Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain. J Neurochem (1970) 3.42
The fluorometric assay of catecholamines and related compounds: improvements and extensions to the hydroxyindole technique. Anal Biochem (1968) 2.09
Comparative effects of p-chloroamphetamine and p-chloro-N-methylamphetamine on rat brain norepinephrine, serotonin and 5-hydroxyindole-3-acetic acid. Biochem Pharmacol (1970) 1.69
Tryptophan hydroxylase inhibition: the mechanism by which p-chlorophenylalanine depletes rat brain serotonin. Mol Pharmacol (1967) 1.62
Pharmacological studies with the serotonin precursor, 5-hydroxytryptophan. J Pharmacol Exp Ther (1958) 1.44
Further evidence for a central hypotensive action of alpha-methyldopa in both the rat and cat. Br J Pharmacol (1973) 1.25
Long-lasting selective depletion of brain serotonin by 5,6-dihydroxytryptamine. Acta Physiol Scand Suppl (1971) 1.05
An improved method for the fluorimetric determination of 5-hydroxytryptamine in tissues. Acta Physiol Scand (1967) 1.00
Localization of indolealkylamines in CNS. Adv Pharmacol (1968) 0.91
Central nervous system mechanisms responsible for blood pressure elevation induced by p-chlorophenylalanine. J Pharmacol Exp Ther (1972) 0.88
Serotonin levels in vascular tissue and the effects of a serotonin synthesis inhibitor on blood pressure in hypertensive rats. Clin Exp Pharmacol Physiol (1975) 0.87
Similarities between behavioral and pharmacological actions of yohimbine and 5-hydroxytryptophan in the conscious dog. Eur J Pharmacol (1970) 0.86
Evidence for a degeneration of indoleamine containing nerve terminals in rat brain, induced by 5,6-dihydroxytryptamine. Z Zellforsch Mikrosk Anat (1972) 0.85
Effect of central inhibition of the 1-amino acid decarboxylase on the hypotensive action of 5-HT precursors in cats. Eur J Pharmacol (1974) 0.84
Effects of 5-hydroxytryptophan on arterial blood pressure, body temperature and tissue monoamines in the rat. Acta Pharmacol Toxicol (Copenh) (1971) 0.83
The effect of central serotonin depletion on DOCA-saline hypertension in the rat. Cardiovasc Res (1974) 0.79
Behavioral and biochemical effects of p-chlorophenylalanine, 3-chlorotyrosine and 3-chlorotyramine. A proposed mechanism for inhibition of self-stimulation. Neuropharmacology (1972) 0.78
Effects of p-chlorophenylalanine on blood pressure and heart rate in normal rabbits and rabbits with neurogenic hypertension. Clin Exp Pharmacol Physiol (1975) 0.77
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell (1998) 12.66
Impact of covert duplicate publication on meta-analysis: a case study. BMJ (1997) 7.01
The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain (1997) 5.29
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res (1985) 5.09
Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain (2000) 4.93
Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ (2001) 4.81
Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol (1986) 4.75
Using numerical results from systematic reviews in clinical practice. Ann Intern Med (1997) 4.38
Role of toxigenic and invasive bacteria in acute diarrhea of childhood. N Engl J Med (1975) 4.23
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ (2001) 3.76
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
A systematic review of antidepressants in neuropathic pain. Pain (1996) 3.09
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology (1997) 2.93
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrob Agents Chemother (1986) 2.74
Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage (1999) 2.71
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet (1992) 2.34
An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain (2000) 2.27
Systematic review of systematic reviews of acupuncture published 1996-2005. Clin Med (2006) 2.24
Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24
Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst (1996) 2.17
BMA approves acupuncture. BMA report is wrong. BMJ (2000) 2.16
Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain (2000) 2.12
A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. BMJ (1997) 2.10
Intravenous ketamine for CRPS: Making too much of too little? Pain (2010) 2.02
Relative efficacy of oral analgesics after third molar extraction. Br Dent J (2004) 1.95
Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother (1986) 1.87
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol (1985) 1.86
Triglyceride fatty acids confirm a change in dietary fat. Clin Endocrinol (Oxf) (1977) 1.86
The Evolution and Involution of the Prostate Gland. Am J Pathol (1936) 1.84
Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst (1992) 1.82
Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1984) 1.81
BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol (1986) 1.79
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell (1998) 1.75
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes (2001) 1.75
Oral aspirin in postoperative pain: a quantitative systematic review. Pain (1999) 1.71
Divergent functional properties of ryanodine receptor types 1 and 3 expressed in a myogenic cell line. Biophys J (2000) 1.69
Some patients don't need analgesics after surgery. J R Soc Med (1982) 1.68
Improved glucose control in maturity-onset diabetes treated with high-carbohydrate-modified fat diet. Br Med J (1979) 1.65
Systematic review of the use of honey as a wound dressing. BMC Complement Altern Med (2001) 1.63
Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol (1981) 1.62
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 1.61
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol (2000) 1.58
Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res (1988) 1.55
Gabapentin for acute and chronic pain. Cochrane Database Syst Rev (2005) 1.55
Mediation of hidradenitis suppurativa by androgens. Br Med J (Clin Res Ed) (1986) 1.54
Inhibition by glibenclamide of the vasorelaxant action of cromakalim in the rat. Br J Pharmacol (1989) 1.52
Drugs for neuropathic pain. BMJ (2013) 1.52
Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough? Pain (2001) 1.51
Placebo. Postgrad Med J (2005) 1.51
When placebo controlled trials are essential and equivalence trials are inadequate. BMJ (1998) 1.51
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol (1987) 1.50
Propofol and bradycardia: causation, frequency and severity. Br J Anaesth (1997) 1.47
In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation (2001) 1.46
The biology of ovarian cancer. Semin Oncol (1998) 1.46
Felty's syndrome: long-term follow-up after splenectomy. Ann Intern Med (1971) 1.43
Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res (1988) 1.42
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer (2005) 1.42
Current studies on the pathogenesis of melioidosis. Microbes Infect (1999) 1.42
Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev (2006) 1.41
Single dose oral naproxen and naproxen sodium for acute postoperative pain. Cochrane Database Syst Rev (2004) 1.41
Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol (1984) 1.41
Ovarian cancer biology. Semin Oncol (1991) 1.40
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res (1997) 1.39
The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res (1998) 1.39
Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage (1998) 1.38
Single dose oral ibuprofen and diclofenac for postoperative pain. Cochrane Database Syst Rev (2000) 1.38
Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand (1998) 1.38
Simple test for nocturnal hypoglycaemia in diabetic patients. Lancet (1979) 1.37
Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res (1984) 1.35
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer (1990) 1.35
Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand (2005) 1.34
Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage (2000) 1.33
Role of porins in intrinsic antibiotic resistance of Pseudomonas cepacia. Antimicrob Agents Chemother (1987) 1.29
Effects of colloid or crystalloid administration on pulmonary extravascular water in the postoperative period after coronary artery bypass grafting. Anesth Analg (1985) 1.28
The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res (2000) 1.27
Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther (1990) 1.27
Antidepressants and chronic pain. BMJ (1997) 1.26
Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res (1984) 1.25
Quantitative evidence for protein denaturation as the cause of thermal death. Nature (1971) 1.24
Morphine and ibuprofen compared using the cold pressor test. Pain (1988) 1.22
Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res (1996) 1.21
Plasma fentanyl concentrations and clinical observations during and after operation. Br J Anaesth (1979) 1.21
An oral buprenorphine and paracetamol combination compared with paracetamol alone: a single dose double-blind postoperative study. Br J Clin Pharmacol (1981) 1.20
Systematic review of outpatient services for chronic pain control. Health Technol Assess (1997) 1.19
Postoperative orthopaedic pain--the effect of opiate premedication and local anaesthetic blocks. Pain (1988) 1.19
Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res (1995) 1.18
The radioimmunoassay of buprenorphine. Eur J Clin Pharmacol (1980) 1.17
Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides (1999) 1.15
Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res (1994) 1.14
Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy. Clin Endocrinol (Oxf) (1987) 1.13
Indwelling catheters for direct recording of arterial blood pressure and intravenous injection of drugs in the conscious rat. J Pharm Pharmacol (1976) 1.13
Clinical effects of buprenorphine during and after operation. Br J Anaesth (1980) 1.12
Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res (1985) 1.12
Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst (1989) 1.11